Onkologie. 2020:14(3):107 | DOI: 10.36290/xon.2020.020

Inflamatorní lymfomy

prof. MUDr. Vít Procházka, Ph.D.
Hemato-onkologická klinika FN Olomouc

Published: June 2, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Procházka V. Inflamatorní lymfomy. Onkologie. 2020;14(3):107. doi: 10.36290/xon.2020.020.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Mittal D, Gubin MM, Schreiber RD, et al. New insights into cancer immunoediting and its three component phases - elimination, equilibrium and escape. Curr Opin Immunol. 2014 Apr; 27: 16-25. Go to original source... Go to PubMed...
    2. Gordon SR, Maute RL, Dulken BW, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017 May 25; 545(7655): 495-499. Go to original source... Go to PubMed...
    3. Roemer MGM, Redd RA, Cader FZ, et al. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. J Clin Oncol. 2018 Apr 1; 36(10): 942-950. Go to original source... Go to PubMed...
    4. Carreau NA, Diefenbach CS. Immune targeting of the microenvironment in classical Hodgkin's lymphoma: insights for the hematologist. Ther Adv Hematol. 2019 May 3. Go to original source... Go to PubMed...
    5. Matsuki E, Younes A. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma. Curr Treat Options Oncol. 2016 Jun; 17(6): 31. Go to original source... Go to PubMed...
    6. Kline J, Godfrey J, Ansell SM, et al. The immune landscape and response to immune checkpoint blockade therapy in lymphoma. Blood. 2020 Feb 20; 135(8): 523-533. Go to original source... Go to PubMed...
    7. Kredátusová A, Hanáčková V, Lukáąová M, Urbánková H, Procházka V. Voµná nádorová DNA u pacientov s Hodgkinovým lymfómom. Onkologie 2020; 14(3): 122-125. Go to original source...
    8. Urbánková H, Vatolíková M, Procházka V. Primární mediastinální difuzní B-velkobuněčný lymfom: význam genetických změn. Onkologie 2020; 14(3): 117-121. Go to original source...
    9. Hanáčková V, Procházka V. Primární mediastinální B-velkobuněčný lymfom: přínos pozitronové emisní tomografie. Onkologie 2020; 14(3): 114-116. Go to original source...
    10. Jirkuvová A, Procházka V, Obr A. Aktuální pohled na diagnostiku a léčbu primárních lymfomů centrálního nervového systému. Onkologie 2020; (14)3: 110-113. Go to original source...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.